FDA Fees to Review Drugs Would Be Unfrozen in House Bill

About $1 billion in annual fees that Pfizer Inc., Medtronic Inc. and other drug and device companies pay the U.S. to review new products would be exempt from federal budget cuts under a bipartisan bill proposed in Congress.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.